Free Newsletter
Courts more open to patent-busting
Patents aren't just an issue in Thailand, either. These days, drugmakers are having a more difficult time keeping patent protection on their products, the Financial Times notes. Ever since top U.S. courts said last spring that "obviousness" could derail a patent, some of pharma's protections have been in peril. Particularly, of course, those patents on meds that are just tweaked-up versions of existing drugs, such as extended-release formulations. Last week, a trial court nullified Bayer's patent on its Yasmin contraceptive for obviousness.
Lehman Bros. estimates that a quarter of 2008 pharma revenue will be at risk from generics by 2012, the Times reports. An additional 9 percent would be if drugmakers lose a lot of lawsuits. There's some hope, though; you'll recall that just yesterday generics maker Teva lost its bid to flatten Pfizer's patents on the painkiller Celebrex.
- read the story in the FT
Related Articles:
Officials toss Genentech antibody patent. Report
Patent ruling threatens $300M in Genentech revenue. Report
BMS is lead player in patent-approval race. Report
Comments
Post new comment
Paid Research Reports
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
- Optimizing Lifecycle Management: Maximizing commercial lifespan through label expansion and combination products
- The CRO Market Outlook: Emerging markets, leading players and future trends
- Pharmaceutical Sales Force Effectiveness Strategies
- Commercial Insight: Influenza Vaccines and Antivirals - The pandemic's long-term impact





